PMEPA1 Antibody

What is the optimal application spectrum for PMEPA1 antibodies?

PMEPA1 antibodies demonstrate versatility across multiple experimental applications. Current validation data indicates successful application in Western Blot (WB), Immunohistochemistry (IHC), Immunofluorescence (IF), and ELISA methodologies, with specific dilution recommendations for each application:

Importantly, optimal dilutions remain sample-dependent and should be determined empirically for each specific experimental context. Research findings indicate successful detection in various cell lines including L02 cells and U2OS cells for WB applications, and human ovary tumor tissue for IHC applications .

What are the critical storage parameters for maintaining PMEPA1 antibody efficacy?

PMEPA1 antibodies are typically supplied in liquid form with PBS containing 0.02% sodium azide and 50% glycerol at pH 7.3. Optimal storage conditions include:

• Storage temperature: -20°C

• Expected stability: One year after shipment when properly stored

• Aliquoting: Not generally necessary for -20°C storage

• Freeze/thaw cycles: Should be minimized to preserve antibody integrity

For antibodies intended for immunohistochemical applications, some formulations may contain 0.05% BSA and 0.05% sodium azide in 10mM phosphate buffered saline .

What species reactivity should researchers expect from PMEPA1 antibodies?

The species reactivity profile is antibody-dependent, with commercially available options demonstrating various reactivity patterns:

When planning multi-species studies, researchers should verify reactivity through literature citations or preliminary testing, as theoretical cross-reactivity based on sequence homology does not always translate to functional recognition .

How should researchers approach PMEPA1 antibody validation for tumor microenvironment studies?

Given PMEPA1's significant role in tumor-immune interactions, comprehensive validation for tumor microenvironment (TME) studies should incorporate:

• Cross-validation with multiple detection methods: Combine IHC with flow cytometry or IF techniques to confirm cellular localization.

• Parallel analysis of key interacting molecules: Research indicates that PMEPA1 expression strongly correlates with immunomodulators (chemokines, MHC-s, immune stimulators and receptors) and is positively correlated with several immune checkpoints including PD-1 (PDCD1), PD-L1 (CD274), CTLA-4, and TIM-3 (HAVCR2) .

• Cell-type specific controls: Include positive controls from cell populations with established PMEPA1 expression patterns. Experimental data shows differential PMEPA1 expression between tumor cells, tumor-associated macrophages (TAMs), cancer-associated fibroblasts (CAFs), and other stromal components .

• Knockout/knockdown validation: Utilize CRISPR/Cas9-mediated PMEPA1 knockout models to establish antibody specificity, as demonstrated in breast cancer studies .

Research findings demonstrate that PMEPA1 expression correlates with infiltration levels of macrophages, CAFs, MDSCs, monocytes, and neutrophils, but negatively correlates with CD8+ T cells, CD4+ T cells, and B cells infiltration, making it crucial to validate antibody specificity in complex tumor samples .

What protocols should be optimized when using PMEPA1 antibodies for immunohistochemistry in formalin-fixed paraffin-embedded (FFPE) tissues?

For optimal IHC results with PMEPA1 antibodies in FFPE tissues, researchers should consider:

• Antigen retrieval optimization: Data indicates superior results with Tris-EDTA buffer pH 9.0, although citrate buffer pH 6.0 can serve as an alternative antigen retrieval solution .

• Blocking optimization: Extensive blocking (5% normal serum, 1% BSA, 0.1% Triton X-100) is recommended to minimize non-specific binding, particularly in tissues with high stromal content.

• Signal amplification consideration: For tissues with expected low PMEPA1 expression, polymer-based detection systems offer superior sensitivity compared to standard avidin-biotin methods.

• Multiplex staining approaches: When investigating PMEPA1 in the tumor microenvironment, sequential staining protocols with macrophage markers (CD68) have successfully demonstrated co-localization patterns as shown in research findings .

• Control selection: Include both positive controls (human ovary tumor tissue has demonstrated consistent positivity) and negative controls (antibody diluent only) in each experiment .

In published immunohistochemical analyses of bladder cancer specimens, PMEPA1 expression positively correlated with T-classification and tumor grade, making proper technique standardization critical for reproducible results .

How should researchers interpret discrepancies between PMEPA1 protein detection by different antibodies across various cancer models?

Discrepancies in PMEPA1 detection between antibodies may stem from several factors requiring careful interpretation:

• Isoform-specific recognition: PMEPA1 exists in multiple isoforms (a, b, c, d) with distinct extracellular regions. Research has identified PMEPA1 isoform d as the major isoform expressed after TGF-β stimulation in breast cancer cells . Antibodies targeting different epitopes may preferentially recognize specific isoforms.

• Context-dependent post-translational modifications: The functional domains of PMEPA1, including PY motifs and Smad-interaction motifs (SIM), undergo regulatory modifications that may mask epitopes in a context-dependent manner.

• Sub-cellular localization variations: Membrane-bound isoforms (a and b) localize to the Golgi apparatus while isoform c lacks the transmembrane domain and remains cytosolic . This differential localization affects antibody accessibility in fixed samples.

• Expression heterogeneity in cancer subtypes: Research demonstrates that PMEPA1 expression varies significantly between molecular subtypes of bladder cancer and is associated with distinct tumor microenvironments .

When encountering discrepancies, researchers should:

• Compare the immunogen sequences between antibodies

• Verify results with multiple antibodies targeting different epitopes

• Use genetic approaches (siRNA/CRISPR) to validate specificity

• Consider tissue/cell-type specific expression patterns documented in the literature

What are the critical considerations when evaluating PMEPA1 expression in relation to TGF-β signaling in tumor samples?

When investigating PMEPA1 in the context of TGF-β signaling, researchers should consider:

• Feedback loop mechanisms: PMEPA1 functions within a negative feedback loop in TGF-β signaling. Research shows that membrane-bound PMEPA1 isoforms (a and b) interact with R-SMADs and ubiquitin ligases to block TGF-β signaling, while cytosolic PMEPA1c does not inhibit this pathway .

• Cancer-type specific effects: PMEPA1's role varies by cancer type—promoting TGF-β oncogenic effects through non-canonical PI3K/AKT signaling in breast and colorectal cancer, while potentially inhibiting bone metastasis in prostate cancer .

• Co-expression patterns: Analyze PMEPA1 in conjunction with other TGF-β pathway components. Research indicates that tumors displaying both TGF-β signaling and high PMEPA1 levels (12% of hepatocellular carcinoma cases) show distinct characteristics compared to tumors with only TGF-β signaling (8%) or only PMEPA1 overexpression (9%) .

• Immune contexture correlation: Evidence shows that HCCs with high PMEPA1 and active TGF-β signaling demonstrate immune exhaustion features, which impacts interpretation of treatment response data .

Data from hepatocellular carcinoma research revealed that PMEPA1 is overexpressed in 18% of HCC samples, with PMEPA1 upregulation linked to TGF-β activation, immune exhaustion, and aggressive phenotypes .

How can researchers effectively employ PMEPA1 antibodies in multi-parameter analyses of the tumor immune microenvironment?

For sophisticated tumor immune microenvironment analyses using PMEPA1 antibodies:

• Multiplex immunofluorescence approaches: Combine PMEPA1 antibodies with markers for specific immune cell populations. Research has established significant correlations between PMEPA1 expression and:

  • Tumor-associated macrophages (TAMs)

  • Cancer-associated fibroblasts (CAFs)

  • Myeloid-derived suppressor cells (MDSCs)

  • Regulatory T cells (Tregs)

• Spatial transcriptomics integration: Correlate protein expression with spatially-resolved transcriptomic data. Research has employed single-cell RNA sequencing to identify PMEPA1 expression in both HCC tumor and stromal cells, with PMEPA1-expressing tumor cells interacting with CD4+ regulatory T cells and CD4+ CXCL13+ and CD8+ exhausted T cells .

• Digital pathology quantification: Employ image analysis algorithms for quantitative assessment of PMEPA1 expression in relation to immune infiltrates. Studies have demonstrated strong positive correlations between PMEPA1 expression and inflammation, infiltration levels of TAMs, CAFs, MDSCs, and immune/stromal scores in bladder cancer TME .

• Functional validation in relevant models: Complement antibody-based observations with genetic manipulation studies. In vivo research has shown that overexpression of MYC+PMEPA1 leads to hepatocellular carcinoma development in approximately 60% of mice compared to 0% in MYC-only mice .

What methodological approaches should be considered when using PMEPA1 antibodies to investigate its different isoforms and their functional implications?

To effectively study PMEPA1 isoforms:

• Epitope-specific antibody selection: Choose antibodies based on targeted domains. The table below summarizes key structural differences between PMEPA1 isoforms:

• Isoform-specific expression analysis: Use 5' Rapid Amplification of cDNA Ends (RACE) coupled with Western blot analysis to identify specific mRNA variants and protein isoforms, as demonstrated in breast cancer studies identifying TMEPAI isoform d as the major isoform expressed following TGF-β stimulation .

• Domain-specific functional assays: Research indicates that both PPxY (PY) motifs and the Smad-interaction motif (SIM) of TMEPAI are essential for colony and sphere formation in breast cancer cells, suggesting coordinated function of these domains .

• CRISPR/Cas9-mediated knockout complementation: Generate PMEPA1 knockout cell lines and reintroduce specific isoforms individually via lentiviral expression systems, as used in breast cancer studies to elucidate isoform-specific functions .

What are the most effective strategies for using PMEPA1 antibodies to investigate its role in tumor progression and metastasis?

To effectively investigate PMEPA1's role in tumor progression and metastasis:

What strategies can researchers employ to overcome inconsistent PMEPA1 antibody staining in heterogeneous tumor samples?

To address inconsistent PMEPA1 staining in heterogeneous tumors:

• Epitope retrieval optimization: For FFPE tissues, compare multiple antigen retrieval methods. Studies report optimal results using Tris-EDTA buffer (pH 9.0), with citrate buffer (pH 6.0) as an alternative .

• Signal amplification methods: For low expression samples, implement tyramide signal amplification or polymer-based detection systems to enhance sensitivity without increasing background.

• Multi-region sampling: Given PMEPA1's heterogeneous expression pattern in tumors, analyze multiple regions (tumor center, invasive margin, adjacent tissue) from each sample to capture spatial heterogeneity.

• Cell type-specific analysis: Implement dual staining approaches with cell-type specific markers. Research demonstrates differential PMEPA1 expression between tumor cells and stromal components, with significant correlations to TAMs (marked by CD68), CAFs, and MDSCs .

• Digital quantification: Employ automated image analysis to objectively quantify PMEPA1 expression levels, minimizing subjective interpretation biases in heterogeneous samples.

• Control standardization: Include tissue microarrays with known PMEPA1 expression levels as batch controls to standardize staining intensity assessment across experiments.

How should researchers address potential cross-reactivity concerns when using PMEPA1 antibodies in multi-parameter immunoassays?

To address cross-reactivity concerns:

• Absorption controls: Pre-absorb PMEPA1 antibodies with recombinant PMEPA1 protein to confirm specificity. Consider using a peptide array covering the immunogen sequence (amino acids 173-252 of human PMEPA1) and related protein regions to identify potential cross-reactive epitopes .

• Secondary antibody optimization: For multiplex assays, select isotype-specific secondary antibodies and validate using isotype controls. Many PMEPA1 antibodies are rabbit polyclonal IgG, requiring careful selection of secondary antibodies to avoid cross-reactivity in multiplex settings .

• Spectral overlap compensation: For fluorescence-based methods, perform comprehensive spectral compensation, particularly important when studying PMEPA1 alongside other markers in the TME.

• Genetic validation: Use CRISPR/Cas9-mediated PMEPA1 knockout cell lines as definitive negative controls .

• Sequential staining protocols: Implement multi-cycle staining with robust antibody stripping between cycles when studying PMEPA1 alongside multiple markers.

• Alternative detection strategies: When possible, complement antibody-based detection with in situ hybridization for PMEPA1 mRNA to corroborate protein expression patterns.

How might PMEPA1 antibodies be employed in emerging single-cell analysis technologies for tumor heterogeneity studies?

PMEPA1 antibodies could advance single-cell tumor heterogeneity research through:

• Mass cytometry (CyTOF) integration: Incorporate metal-conjugated PMEPA1 antibodies into CyTOF panels to simultaneously measure PMEPA1 expression alongside 40+ other proteins at single-cell resolution, enabling detailed characterization of PMEPA1+ cell populations within the TME.

• Spatial proteomics platforms: Deploy PMEPA1 antibodies in multiplex spatial platforms (e.g., imaging mass cytometry, CODEX, Hyperion) to map PMEPA1 expression spatially in relation to immune cell infiltrates and architectural features.

• Single-cell functional assays: Combine PMEPA1 antibody-based cell sorting with single-cell functional assays to assess the biological behavior of PMEPA1-expressing vs. non-expressing cells within the same tumor.

• Multi-omic integration: Correlate PMEPA1 protein expression with transcriptomic and epigenomic data at single-cell resolution. Research using scRNAseq has already identified PMEPA1 expression in both HCC tumor and stromal cells, revealing potential intercellular interactions between PMEPA1-expressing cells and specific immune populations .

• Lineage tracing studies: Use PMEPA1 antibodies to track clonal evolution and plasticity by monitoring expression changes during tumor progression and treatment response.

What potential exists for using PMEPA1 antibodies in developing therapeutic response biomarkers?

PMEPA1 antibodies show promise for therapeutic response biomarker development:

• Immunotherapy response prediction: Research demonstrates associations between PMEPA1 and immune checkpoint molecules (PD-1, PD-L1, CTLA-4, TIM-3) , suggesting potential utility in predicting immunotherapy response.

• TGF-β pathway inhibitor monitoring: Since PMEPA1 functions within TGF-β signaling negative feedback loops, monitoring its expression may help evaluate responses to TGF-β pathway inhibitors currently in clinical development.

• Molecular subtyping refinement: Studies show that PMEPA1 expression correlates with molecular subtypes in bladder cancer , potentially refining patient stratification for targeted therapies.

• Liquid biopsy development: Investigate circulating tumor cells for PMEPA1 expression as a minimally invasive monitoring approach.

• Combination therapy rationale: The association between PMEPA1, TGF-β signaling, and immune exhaustion in HCC provides rationale for exploring combination therapies targeting both pathways simultaneously.

• Resistance mechanism identification: Monitor PMEPA1 expression changes during treatment to identify adaptive resistance mechanisms, particularly in therapies targeting TGF-β signaling or androgen receptor pathways where PMEPA1 plays regulatory roles.